Department of Oncology, Medical Oncology Unit, San Donato Hospital, Via Nenni 20, 52100, Arezzo, Italy.
Department of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, 34129, Trieste, Italy.
Invest New Drugs. 2017 Aug;35(4):518-523. doi: 10.1007/s10637-017-0452-1. Epub 2017 Mar 11.
Ramucirumab is a monoclonal antibody against Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) approved for the treatment of several solid tumours. As shown in recent trials results, new-onset hypertension is one of the most frequent adverse events associated with ramucirumab therapy. Recent studies looked at the quantification of the risk of hypertension in patients receiving other anti-angiogenesis medications. We conducted a meta-analysis of randomized clinical trials with the aim to investigate the incidence and quantify the risk of new-onset hypertension of any grade in patients treated with ramucirumab. Our research suggests that hypertension is frequently associated with ramucirumab therapy, with an OR of 3.60 for any grade of hypertension and an even stronger correlation with grade 3-4 hypertension (OR 4.16). These data suggest that a strict monitoring, as well as early intervention protocols, are recommended in patients receiving the drug.
雷莫芦单抗是一种针对血管内皮生长因子受体-2（VEGFR-2）的单克隆抗体，已被批准用于治疗多种实体瘤。正如最近的试验结果所示，新发高血压是与雷莫芦单抗治疗相关的最常见不良事件之一。最近的研究着眼于量化接受其他抗血管生成药物治疗的患者发生高血压的风险。我们对随机临床试验进行了荟萃分析，旨在调查接受雷莫芦单抗治疗的患者新发任何级别高血压的发生率和量化风险。我们的研究表明，高血压与雷莫芦单抗治疗密切相关，任何级别高血压的 OR 为 3.60，与 3-4 级高血压的相关性更强（OR 4.16）。这些数据表明，建议在接受该药物治疗的患者中进行严格监测和早期干预方案。
